ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lonza is expanding microbial manufacturing with a new facility in Visp, Switzerland, that will serve the French drugmaker Servier and other customers. In particular, the facility will boost output of l-asparaginase, which Lonza has made for Servier since 2009. The enzyme is the basis of Servier’s chemotherapy for acute lymphoblastic leukemia, a white blood cell cancer. The plant, scheduled to open by the end of 2022, should create 100 jobs, Lonza says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter